Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

NCT01859182 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gallbladder
Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Localized Unresectable Adult Primary Liver Cancer
Metastatic Extrahepatic Bile Duct Cancer
Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Stage II Gallbladder Cancer
Stage IIIA Gallbladder Cancer
Stage IIIB Gallbladder Cancer
Stage IVA Gallbladder Cancer
Stage IVB Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Cancer

Interventions

DRUG: selumetinib
DRUG: Akt inhibitor MK2206
OTHER: laboratory biomarker analysis
OTHER: pharmacogenomic studies
PROCEDURE: quality-of-life assessment

Sponsor

National Cancer Institute (NCI)